IRLAB Therapeutics AB (OSTO:IRLAB A) ROCE %: 125.39% (As of Mar. 2026)

What is IRLAB Therapeutics AB ROCE %?

IRLAB Therapeutics AB OSTO:IRLAB A -0.16% 35 ROCE % is 125.39% as of Mar. 2026. GuruFocus rates OSTO:IRLAB A with a GF Score™ of 35/100 and a GF Value™ of kr11.78 (Possible Value Trap). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IRLAB Therapeutics AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 125.39%.

IRLAB Therapeutics AB (OSTO:IRLAB A) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

IRLAB Therapeutics AB ROCE % Related Terms

IRLAB Therapeutics AB ROCE % Historical Data

* Premium members only.

The historical data trend for IRLAB Therapeutics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB ROCE % Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

13.87

-32.58

-82.32

-82.30

-275.15

IRLAB Therapeutics AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-522.62	0.00	-246.73	-154.13	125.39

35GF Score

IRLAB Therapeutics AB OSTO:IRLAB A

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

IRLAB Therapeutics AB ROCE % Calculation

IRLAB Therapeutics AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-92.023	/	( ( (136.212 - 100.041)	+	(140.804 - 110.086) )	/ 2 )
	=	-92.023	/	( (36.171	+	30.718)	/ 2 )
	=	-92.023	/	33.4445
	=	-275.15 %

IRLAB Therapeutics AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	44.236	/	( ( (140.804 - 110.086)	+	(135.031 - 95.189) )	/ 2 )
	=	44.236	/	( ( 30.718	+	39.842 )	/ 2 )
	=	44.236	/	35.28
	=	125.39 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 125.39% mean?

IRLAB Therapeutics AB (OSTO:IRLAB A) has a ROCE % of 125.39% as of Mar. 2026.

Is IRLAB Therapeutics AB's ROCE % too high?

IRLAB Therapeutics AB's current ROCE % is 125.39%. Overall, IRLAB Therapeutics AB has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does IRLAB Therapeutics AB's ROCE % compare to VRTX and REGN?

IRLAB Therapeutics AB's ROCE % of 125.39% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. IRLAB Therapeutics AB's current ROCE % is 125.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is IRLAB Therapeutics AB stock overvalued right now?

Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.78, compared to a current price of kr1.22 — trading 89.7% below its estimated fair value. The current ROCE % is 125.39%. IRLAB Therapeutics AB's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current ROCE % is 125.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.22 is trading 89.7% below its estimated GF Value™ of kr11.78. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

ROCE %: 125.39%
GF Value™: kr11.78 vs. price of kr1.22 (89.7% below fair value)
GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRLAB Therapeutics AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:BIOVIC B NGM:GTAB B OSTO:ANNX OSTO:ACOU OSTO:CMOTEC B OSTO:ONCOZ OSTO:SIMRIS B OSTO:ATORX OSTO:PILA OSTO:FLUI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 6IRA:Germany

Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

35GF Score

Get the complete analysis for OSTO:IRLAB A

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.22

Price

kr11.78

GF Value

View OSTO:IRLAB A Analysis

See ROCE % data for all stocks →